Ironwood Pharmaceuticals (IRWD) Convertible Debt (2015 - 2025)

Ironwood Pharmaceuticals has disclosed Convertible Debt across 11 years of filings, most recently posting $199.2 million for Q1 2025.

• Convertible Debt for Q1 2025 came in at $199.2 million, changed 0.34% year-over-year; the trailing twelve-month figure through Mar 2025 was $199.2 million (changed 0.34% YoY), and the FY2024 annual result was $199.0 million, changed 0.34% from the prior year.
• Convertible Debt came in at $199.2 million for Q1 2025 at Ironwood Pharmaceuticals, roughly flat from $199.0 million in the prior quarter.
• In the past five years, Convertible Debt ranged from a high of $436.1 million in Q1 2021 to a low of $198.0 million in Q2 2023.
• The 5-year median for Convertible Debt is $329.2 million (2021), against an average of $294.3 million.
• Across the five-year window, Convertible Debt rose 20.14% in 2022 and sank 49.96% in 2024, its largest moves.
• Ironwood Pharmaceuticals' Convertible Debt stood at $337.3 million in 2021, then increased by 17.47% to $396.3 million in 2022, then plunged by 49.95% to $198.3 million in 2023, then gained by 0.34% to $199.0 million in 2024, then advanced by 0.09% to $199.2 million in 2025.
• The last three Convertible Debt figures came in at $199.2 million (Q1 2025), $199.0 million (Q4 2024), and $198.8 million (Q3 2024), per Business Quant data.